MAO‐B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of clinical pharmacology

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.1096PMID 29578580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological Treatment of Parkinson’s Disease

  2018cited by this paper
• How close are we to individualized medicine for Parkinson’s disease?

  2016cited by this paper
• Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.

  2016cited by this paper
• Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease.

  2015cited by this paper
• The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis

  2014cited by this paper
• Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease

  2013cited by this paper
• Analysis of PARK2 gene exon rearrangements in Russian patients with sporadic Parkinson's disease

  2012cited by this paper
• Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.

  2012cited by this paper
• Epidemiology of Alzheimer disease.

  2012cited by this paper
• The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.

  2012cited by this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cited by this paper
• From reinforcement learning models to psychiatric and neurological disorders

  2011cited by this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cited by this paper
• The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications

  2008cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.

  2007cited by this paper
• Genetic polymorphism of catechol‐O‐methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease

  2005cited by this paper
• Present and future drug treatment for Parkinson’s disease

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• The effect of monoamine oxidase B (MAOB) and catechol‐O‐methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease

  2004cited by this paper
• Perspectives on MAO-B in aging and neurological disease

  2004cited by this paper
• DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson's disease cases and unrelated controls

  2004cited by this paper
• Are men at greater risk for Parkinson’s disease than women?

  2004cited by this paper
• Association between Catechol-O-Methyltransferase Gene Polymorphisms and Wearing-Off and Dyskinesia in Parkinson’s Disease

  2003cited by this paper
• Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson's disease

  2002cited by this paper
• The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese

  2001cited by this paper
• Investigation of the functional effect of monoamine oxidase polymorphisms in human brain

  2001cited by this paper
• Platelet monoamine oxidase activity is related to MAOB intron 13 genotype

  2000cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• Variability and validity of polymorphism association studies in Parkinson’s disease

  2000cited by this paper
• BioEstat 2.0: aplicações estatísticas nas áreas das ciências biológicas e médicas

  2000cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Parkinsonism

  1967cited by this paper

• Ghrelin-based interventions in preclinical models of Parkinson's disease: a systematic review.

  2026cites this paper
• PROTAC-based degradation of catechol-O-methyltransferase for potential treatment of Parkinson’s disease

  2026cites this paper
• Neurovascular Integration Failure and Freezing of Gait: Rethinking Parkinsonism Through a Vascular Lens

  2026influential citation
• An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.

  2026cites this paper
• Association of COMT and MAO-B gene polymorphic variants with sensitivity to dopaminergic therapy in patients with Parkinson’s disease

  2025cites this paper
• Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease

  2025cites this paper
• The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease

  2025cites this paper
• Zebrafish-Based Parkinson's Disease Models: Unveiling Genetic Mechanisms and Therapeutic Pathways.

  2025cites this paper
• Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models

  2025cites this paper
• Age and gender aspects of parkinson's disease

  2025cites this paper
• Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease

  2025cites this paper
• Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease

  2025cites this paper
• How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis

  2025cites this paper
• The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test

  2025cites this paper
• The Relationship Between COMT and MAO-B Gene Polymorphisms with Levodopa in Parkinson’s Disease Patients; A Review

  2024cites this paper
• Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge

  2024influential citation
• Critical evaluation of the current landscape of pharmacogenomics in Parkinson's disease - What is missing? A systematic review.

  2024cites this paper
• Sex difference in human diseases: mechanistic insights and clinical implications

  2024cites this paper
• Addressing the Ethnicity Gap in Catechol O-Methyl Transferase Inhibitor Trials in Parkinson’s Disease: A Review of Available Global Data

  2024cites this paper
• Sex differences in alpha-synucleinopathies: a systematic review

  2023cites this paper
• Sex and gender differences in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis: a narrative review.

  2023cites this paper
• Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.

  2023cites this paper
• Costunolide and Parthenolide Ameliorate MPP+ Induced Apoptosis in the Cellular Parkinson’s Disease Model

  2023cites this paper
• Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities

  2023cites this paper
• Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach

  2023cites this paper
• Sex Differences in the Speech of Persons With and Without Parkinson's Disease.

  2023cites this paper
• Gene signals and SNPs associated with Parkinson's disease: A nutrigenomics and computational prospective insights.

  2023cites this paper
• An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease

  2023cites this paper
• Sex Differences in Parkinson’s Disease: From Bench to Bedside

  2022cites this paper
• Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias.

  2022cites this paper
• Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson's Disease

  2022cites this paper
• Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson’s disease: a systematic review and meta-analysis

  2022cites this paper
• The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson’s Disease

  2022cites this paper
• Association of Catechol-O-Methyltransferase Gene Polymorphisms and Haplotypes in the Levodopa-Induced Adverse Events in Subjects with Parkinson’s Disease

  2022cites this paper
• Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson’s Disease: A Meta-Analysis and Systematic Review

  2022influential citation
• ANTİPARKİNSON İLAÇLARINA VERİLEN BİREYSEL YANITTA FARMAKOGENETİĞİN ROLÜ

  2022cites this paper
• Levodopa responsiveness in Parkinson’s disease: harnessing real-life experience with machine-learning analysis

  2022cites this paper
• Sex and gender differences in movement disorders: Parkinson's disease, essential tremor, dystonia and chorea.

  2022cites this paper
• Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease

  2022cites this paper
• Genetic architecture of Parkinson’s disease subtypes – Review of the literature

  2022influential citation
• Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease

  2022influential citation
• A Systematic Review of Parkinson’s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?

  2021cites this paper
• Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view.

  2021cites this paper
• Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.

  2021cites this paper
• Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease

  2021cites this paper
• Biphenylpiperazine Based MAO Inhibitors: Synthesis, Biological Evaluation, Reversibility and Molecular Modeling Studies.

  2021cites this paper
• Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson’s disease—a meta-analysis

  2021influential citation
• Amelioration of L-DOPA-induced dyskinesia with vitamin D3 in Parkinsonian mice model

  2021cites this paper
• Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease

  2020cites this paper
• Sleep Pharmacogenetics

  2020cites this paper
• Role of Genetic Variations in the Hepatic Handling of Drugs

  2020cites this paper
• Potential Treatment of Parkinson's Disease, Using Last-Generation Carbon Nanotubes: A Bimolecular In-Silico Study

  2020cites this paper
• Sex differences in movement disorders

  2020cites this paper
• Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.

  2020cites this paper
• Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson’s disease patients: a population-based cohort study

  2020cites this paper
• Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease

  2020influential citation
• Contribution of Five Functional Loci of Dopamine Metabolism-Related Genes to Parkinson’s Disease and Multiple System Atrophy in a Chinese Population

  2020cites this paper
• High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.

  2020cites this paper
• L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.

  2019cites this paper
• Synthesis and evaluation of nitrocatechol derivatives of chalcone as inhibitors of monoamine oxidase and catechol-O-methyltransferase

  2019cites this paper
• Impaired dopamine metabolism in Parkinson’s disease pathogenesis

  2019cites this paper
• Association of Polymorphic Variants of Key Histamine Metabolism Genes and Histamine Receptor Genes with Multifactorial Diseases

  2019cites this paper
• Sleep Pharmacogenetics: The Promise of Precision Medicine.

  2019cites this paper
• Parkinson’s Disease in Women and Men: What’s the Difference?

  2019cites this paper
• Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease

  2019cites this paper
• Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?

  2018cites this paper
• L‐DOPA for Parkinson's disease—a bittersweet pill

  2018cites this paper
• Pharmacogenetics and levodopa induced motor complications

  2018cites this paper
• АМАНТАДИНЫ: ОПЫТ ПРИМЕНЕНИЯ ПРИ БОЛЕЗНИ ПАРКИНСОНА

  2016cites this paper